Pharmacy’s Fantastic when the Marrows Aplastic: Pharmacologic Management of Aplastic Anemia

<p>Devon S. Stonerock, PharmD (<a href='https://twitter.com/DevonStoneRx'>@DevonStoneRx</a>) describes the underlying pathophysiology driving the development and progression of aplastic anemia, outlines treatment options based on patient specific factors and recognizes key toxicities, drug interactions, and administration considerations for patients receiving immunosuppressive therapy.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>